博九娱乐网

OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer that are underserved by available therapies. Using a proven structure-based drug design platform, they are building a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing…More OKI-219, a selective PI3K伪H1047R inhibitor, as its lead program. OnKure aims to become the leader in targeting oncogenic PI3K伪 and has multiple programs to enable optimal targeting of this critical oncogene.